Disease and Economic Burden Averted by Hib Vaccination in 160 Countries: A Machine-Learning Analysis
文献类型：期刊论文
| 作者 | Zhou, Dachuang1,6; Chan, Siyang1,6; Zhong, Yimei1,6; Xu, Zhehong2; Wang, Jun3; Wang, Yuntian4,5; Gao, Yiyang1,6; Xia, Yuting1,6; Zhang, Di1,6; Tang, Wenxi1,6 |
| 刊名 | VACCINES
 |
| 出版日期 | 2025-11-27 |
| 卷号 | 13期号:12页码:12 |
| 关键词 | Haemophilus influenzae type b cost-effectiveness vaccination |
| DOI | 10.3390/vaccines13121197 |
| 英文摘要 | Background: Global immunization against Haemophilus influenzae type b (Hib) has expanded with Gavi support. We estimated health, economic benefits, equity and cost-effectiveness in 159 countries (1990-2021), and projected effects of future introduction in China. Methods: We used a random forest model to simulate counterfactual scenarios without Hib vaccine introduction in 159 countries (1990-2021) and to project effects of Hib vaccine introduction in China over the next decade. Ten variables were sourced from the World Bank and WHO; Hib disease burden estimates were from the Global Burden of Disease Study 2021. We compared counterfactual and actual results to quantify benefits, equity, and cost-effectiveness. Extensive uncertainty analyses were performed. Results: Between 1990 and 2021, Hib immunization averted an estimated 1,321,123 (95% uncertainty interval [UI] 32,034-2,723,304) deaths and 90,973,504 (95% UI 3,573,718-197,099,799) disability-adjusted life-years globally. Greatest health and economic gains occurred in Africa and low- and middle-income countries (LMICs). Deaths averted decreased with later vaccine introduction (Pearson's r = -0.56). Vaccination did not improve health equity, and access remains limited in Africa and LMICs. Hib immunization was cost-saving in all countries. In China, introduction at any point in the next decade would provide health and economic benefits and be cost-effective, with earlier introduction yielding greater gains. Conclusions: Hib immunization provide substantial, cost-effective health and economic benefits globally. Persistent inequities in vaccine access for LMICs require targeted solutions. Policymakers in China should consider these findings for future vaccine introduction. |
| WOS关键词 | INFLUENZAE TYPE-B ; MIDDLE-INCOME COUNTRIES ; CONJUGATE VACCINE ; CHILDHOOD IMMUNIZATION ; HEALTH ; IMPACT ; ELIMINATION ; INFANTS ; ERA |
| 资助项目 | National Natural Science Foundation of China[2023YFVA1002] ; Jiangsu Provincial Drug Administration[202307] |
| WOS研究方向 | Immunology ; Research & Experimental Medicine |
| 语种 | 英语 |
| WOS记录号 | WOS:001647409200001 |
| 出版者 | MDPI |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/322450]  |
| 专题 | 国家级研究中心_原创新药研究全国重点实验室 |
| 通讯作者 | Tang, Wenxi |
| 作者单位 | 1.China Pharmaceut Univ, Sch Int Pharmaceut Business, Dept Publ Affairs Management, 639 Longmian Rd, Nanjing 211198, Peoples R China 2.Xiamen Univ, Paula & Gregory Chow Inst Studies Econ, Xiamen 361005, Peoples R China 3.Chinese Acad Sci, Shanghai Inst Mat Med, Mol Imaging Ctr, State Key Lab Drug Res, Shanghai 201203, Peoples R China 4.Chinese Acad Sci, Inst Automat, State Key Lab Multimodal Artificial Intelligence S, Beijing 100190, Peoples R China 5.Hainan Univ, Sch Informat & Commun Engn, Haikou 570228, Peoples R China 6.China Pharmaceut Univ, Ctr Pharmacoecon & Outcomes Res, Nanjing 211198, Peoples R China |
| 推荐引用方式 GB/T 7714 | Zhou, Dachuang,Chan, Siyang,Zhong, Yimei,et al. Disease and Economic Burden Averted by Hib Vaccination in 160 Countries: A Machine-Learning Analysis[J]. VACCINES,2025,13(12):12. |
| APA | Zhou, Dachuang.,Chan, Siyang.,Zhong, Yimei.,Xu, Zhehong.,Wang, Jun.,...&Tang, Wenxi.(2025).Disease and Economic Burden Averted by Hib Vaccination in 160 Countries: A Machine-Learning Analysis.VACCINES,13(12),12. |
| MLA | Zhou, Dachuang,et al."Disease and Economic Burden Averted by Hib Vaccination in 160 Countries: A Machine-Learning Analysis".VACCINES 13.12(2025):12. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。